INTRODUCTION
============

The high prevalence of malnutrition in India is alarming, as is evident from the recent National Family Health Survey (NFHS-4 2015--2016) report, which pegs prevalence of stunting at 41.2% and underweight at 38.2% in rural India \[[@B1]\]. The cyclic relationship between malnutrition and infections is well-known; infections worsen the nutritional status and, conversely, poor nutritional status results in increased susceptibility to infections, thereby leading to deteriorating health of the child \[[@B2]\]. Micronutrient malnutrition especially increases susceptibility to infections, since micronutrients play an important role in various mechanisms of the immune system, such as barrier integrity, production of immune cells, etc. \[[@B3]\].

Currently in the limelight, vitamin D is known to play a key role as an immunomodulator. Activation of toll-like receptors on monocytes and macrophages by foreign antigens results in increased expression of the CYP27B1 and vitamin D receptor (VDR) genes, with subsequent increase in the synthesis of both 1,25-dihydroxyvitamin D and VDR. The 1,25-dihydroxyvitamin D binds with VDR and induces synthesis of the antimicrobial peptides, cathelicidin (LL-37) and defensin, which are responsible for antimicrobial activities \[[@B4]\].

Maintaining the serum 25(OH)D levels consistently ≥ 75 nmol/L is suggested to be conducive to eliciting an appropriate immune response \[[@B5]\]. However, in spite of India being a tropical country with abundant sunshine throughout the year, a prevalence of up to 70--90% vitamin D deficiency (serum 25(OH)D \< 50 nmol/L) has been reported among Indians \[[@B6][@B7][@B8]\]. The reasons for vitamin D deficiency among Indians are multifaceted, and are associated with avoidance of sunshine (due to urbanization, cultural or religious reasons), consumption of calcium-deficient and phytate-rich, predominantly vegetarian diets, and genetic reasons (eg., up-regulation of CYP24A1 gene, resulting in increased degradation of 25(OH)D) \[[@B6]\]. Calcium intake is an important factor to help overcome vitamin D deficiency; poor calcium intake is demonstrated to cause rapid degradation of serum 25(OH)D by inducing secondary hyperparathyroidism \[[@B9][@B10]\]. Diets of Indian children are found to be severely lacking in calcium, meeting only about 30% of the recommended dietary allowances (RDA) \[[@B11]\]. Hence, while calcium may not be directly involved in immune regulation, adequate calcium intakes are required to maintain the 25(OH)D concentration in the optimal range to facilitate maintenance of the immune regulating benefits \[[@B12]\].

Zinc is an essential micronutrient which plays a vital role in the functioning of the immune system, and zinc deficiency is characterized by depressed immune function. High prevalence of zinc deficiency has been reported among children under 5 years \[[@B13]\] and adolescent girls in India \[[@B14]\].

While there are reports from India on infections among 6--12 year old children and strategies to reduce them, most are focused on the urban population \[[@B15][@B16]\]. Trials aimed at reducing infections in this age group in rural India are scant, in spite of knowledge of prevalence of infections and malnutrition among them \[[@B17][@B18]\].

Studies determining the effect of vitamin D supplementation on incidence of infections in children have yielded varied results. Quarterly supplementation with 100,000 IU oral vitamin D for 18 months had no impact on reducing the incidence of either pneumonia \[[@B19]\] or diarrheal illness \[[@B20]\] in 1 to 11 month old infants in Kabul. Contrarily, another report indicated that supplementation with 1,200 IU cholecalciferol/day for 4 months, in children aged 6 to 15 years in Japan, reduces the incidence of wintertime influenza A \[[@B21]\].

To date, there is no consensus on the dose and frequency of vitamin D supplementation required to induce an immune response \[[@B22]\]. Due to lack of conclusive evidence, it is important to study the effect of vitamin D supplementation on the occurrence of childhood infections in a population having a high prevalence of infections.

Trials from Turkey suggest that zinc supplementation contributes to reduction in severity, but not the duration, of common colds in 5 year old children \[[@B23]\]; another study reports the reduction of morbidity due to diarrhea in rural West African children aged 6 to 31 months \[[@B24]\]. Other trials, however, failed to demonstrate any benefits of zinc supplementation on the incidence of diarrhea or respiratory tract infections \[[@B25]\]. However, we found no intervention trial aimed at assessing the effect of zinc supplementation on infections in children aged 6--12 years in India.

Summarizing the literature available, we found that there is a high prevalence of infections among schoolchildren aged 6--12 years in rural India. Furthermore, several reports indicate both vitamin D and zinc deficiency among Indian children, with very few studies on interventions using vitamin D or zinc supplements to reduce infections among children aged 6--12 years in rural areas. Therefore, we planned this randomized, double-blind, placebo-controlled trial with the primary objective of assessing the effect of supplementation with vitamin D3 (cholecalciferol) along with calcium, or supplementation with zinc, on the occurrence of infections in rural Indian schoolchildren. Our hypothesis is that there would be significant reduction in the occurrence of infections among the participants in both the vitamin D as well as the zinc arms of the trial, as compared to participants in the placebo arm.

SUBJECTS AND METHODS
====================

Trial design and participants
-----------------------------

This randomized, double-blind, placebo-controlled trial was conducted in a Public Elementary School (Grade 1 to 4) located in a rural region 65 kms east from Pune city (18°N), Western India. Selection of the school was after surveying rural areas around Pune city to assess site accessibility, subject availability and cooperation of school authorities. We connected with the local governing authority to obtain a list of schools in the area, and 10 schools satisfying the inclusion criteria were short-listed and approached for consent. The final school was randomly selected from the 8 schools which consented for the trial to be executed on their premises.

Inclusion criteria of this study were children between the ages of 6--12 years who were not consuming any supplements or preparations containing vitamin D or calcium or zinc. Our exclusion criteria were children with congenital abnormalities, chronic medical conditions, and conditions which could affect the vitamin D and calcium metabolism.

Totally, 544 children meeting the age criteria were enrolled from the selected school. All parents were approached for consent. Parents of 474 children provided written informed consents, and written informed assents were obtained from the children. Children whose parents had consented underwent a general medical examination by a pediatrician to rule out any medical conditions; 30 children were excluded due to pre-existing conditions including asthma, kidney stones, liver disease, growth hormone deficiency, thalassemia, and suspected neurodevelopmental delay. During blood collection, 9 children were absent. Finally, 435 children were enrolled in this trial. Allocations of children to the three trial arms were as follows: 135 to the vitamin D arm, 150 to the zinc arm, and 150 to the placebo arm ([Fig. 1](#F1){ref-type="fig"}).

Approval for the trial was obtained from the institutional ethics committee (Ethics Committee Jehangir Clinical Development Centre Pvt. Ltd.). The trial was registered with the Clinical Trials Registry-India (CTRI/2014/08/004854).

Study period
------------

The trial was conducted from July 2014 to February 2015. The monsoon season in Pune lasts from July to September every year. Pune, however, experiences adequate sunshine throughout the year, with average sunshine hours of 10.7, 7.5 and 9.4 hours during summer, monsoon and winter, respectively \[[@B26]\].

Supplementation
---------------

a\. Vitamin D Supplementation: A vitamin D-calcium supplement containing 1,000 IU of cholecalciferol (vitamin D3) and 500 mg of calcium as calcium carbonate was administered to the participants randomized to the vitamin D arm. The above supplement composition was decided, since 600-1,000 IU of vitamin D/day is the suggested daily intake for children aged 6--12 years who are at risk of vitamin D deficiency \[[@B27]\]. Additionally, in order to impart extraskeletal benefits by maintaining serum 25(OH)D consistently above 75 nmol/L, a vitamin D intake of at least 1,000 IU/day has been suggested \[[@B27]\].Furthermore, considering that diets of Indian children are deficient in calcium \[[@B11]\], which further exacerbates vitamin D deficiency \[[@B9]\], and the RDA for Indian children aged 6--12 years is 600--800 mg/day \[[@B28]\], we provided a vitamin D supplement containing 500 mg of calcium.b. Zinc Supplementation: A supplement containing zinc sulfate providing 10 mg of zinc was administered to participants in the zinc arm. The RDA of zinc for Indian children aged 6--12 years is 7--9 mg of zinc per day. Since additional recommendations regarding dose, duration and frequency of supplementation are not available, we decided to provide a supplement meeting the RDA requirement for zinc.c. Placebo: The children in the placebo group were administered a tablet containing 10 mg fructose.

Blinding and randomization
--------------------------

The vitamin D-calcium supplement was supplied by Eris Lifesciences Ltd., Ahmedabad, India. The zinc and placebo tablets were manufactured by SDS Nutraceuticals, Karad, India, to appear identical to the vitamin D-calcium tablet. The supplements and placebo were thus, similar looking white, oval-shaped tablets, and each weighing 1,500 mg. These were packed in high-density polyethylene plastic jars and labelled A, B and C. Coding of the supplements was performed by the supplier, and the codes were revealed only after completion of the trial. The trial staff as well as the participants were unaware of the intervention being administered, thereby achieving double blinding.

The cluster randomization method was used to randomly allocate the 435 participants to the three trial arms: vitamin D, zinc and placebo. Each class or grade in the school had 3 divisions, A, B and C, which were categorized as the designated clusters. Children in the A divisions of all 4 classes were administered supplement from the bottles labelled A, those in B divisions were administered supplement from the bottles labelled B, and those in C divisions were administered supplement from the bottles labelled C.

Compliance
----------

The supplementation process was rigorously monitored. Trained social workers administered the supplement/placebo to the participants in the classrooms during the first period, daily for 6 months. Records of supplement intake were maintained in a register, immediately after consumption. Every Saturday, a supplement packet was handed over to the child, with instructions to consume the same on Sunday. Caregivers were also reminded during each home-visit to ensure their child consumed the supplement. Furthermore, on the Monday that followed, it was enquired if the Sunday supplement had been consumed, and this was duly noted in the register.

The compliance percentage was computed as a percent of the number of days the participant consumed the supplement from the total number of days that the supplement was administered.

Demographic and sunlight exposure data
--------------------------------------

Demographic data were collected by administering a questionnaire and interviewing the primary caregiver of the participant. Data regarding parent\'s education and family income were also collected and used to assess the socio-economic status of the family by applying Kuppuswamy\'s method \[[@B29]\].

Sunlight exposure data relating to time of sunlight exposure, duration of exposure, use of cap or sunscreens, length of school uniform, and mode of transport to and from school, were recorded using a validated questionnaire administered to the participant in the presence of the primary caregiver \[[@B30]\].

Living conditions and personal hygiene data
-------------------------------------------

To assess the living conditions and personal hygiene habits of the participants, the primary caregivers were interviewed in the presence of the participants using a validated questionnaire. Primary caregivers were asked about the type of house they lived in, waste disposal habits and water purification methods \[[@B31][@B32]\]. Participants were asked about their personal hygiene habits - how often they brushed their teeth and whether they washed their hands before meals and after visiting washrooms \[[@B31][@B32]\]. Data variables in the living conditions as well as personal hygiene data were scored as 0 for poor condition or habit, 5 for moderate, and 10 for appropriate condition or good habit. These were summarized, and percentages were calculated based on the best score attainable. The living condition percentage scores were coded as follows: \< 50% poor living condition, 50--60% fair, 61--80% good, and \> 80% very good living conditions. Personal hygiene percentage scores were coded as follows: \< 70% poor personal hygiene, 71--80% fair, 81--90% good, and \> 90% very good personal hygiene \[[@B31][@B32]\].

Anthropometric measurements
---------------------------

Using a portable stadiometer (Seca 213 Portable Stadiometer, Germany), standing height was measured to the nearest 0.1 cm. Body weight was measured using the Tanita Body Composition Analyzer (Model BC-420MA). Body mass index (BMI, expressed as kg/m^2^) was calculated using the formula: weight in kg divided by height in meters squared. Ethnic-specific growth references were used to compute height-for-age (HAZ), weight-for-age (WAZ), and BMI-for-age (BAZ) z-scores \[[@B33]\].

Dietary history
---------------

Trained nutritionists recorded dietary history using the 24-hour dietary recall method administered over 3 non-consecutive days, including Sunday or a holiday. For accurate estimation of food intake, participants and their primary caregivers were interviewed jointly. Nutrient intakes were estimated using the C-Diet software \[[@B34]\], which is based on the nutritive values of raw foods \[[@B35]\] and cooked foods \[[@B36]\]. The percentage of each nutrient consumed was calculated as per the RDA for Indian children \[[@B28]\].

Biochemical estimations
-----------------------

Blood collection was performed at two time points: baseline (before the intervention was started, July 2014), and endline (on completion of the supplementation period, March 2015). Venous blood samples were collected between 7 and 9 a.m. by trained phlebotomists, using plain BD Vacutainer blood collection tubes. The participants were instructed to come fasting for the blood collection. Serum separation was achieved within 4 hours of blood collection, by centrifugation at 3,000 rpm for 15 minutes at room temperature. Serum aliquots were stored at −80℃ until further biochemical estimations.

a\. Serum 25(OH)D: The ELISA technique was used for estimation of 25(OH)D using standard kits (DLD diagnostics GMBH, intra-assay CV - 5%; inter-assay CV - 7.8%). The vitamin D status was classified as deficient (\< 50 nmol/L), insufficient (50.0--74.9 nmol/L) and sufficient (≥ 75 nmol/L), based on the 2011 Endocrine Society Practice Guidelines \[[@B27]\]. Since primary objective of this trial was to investigate the immune modulating activity of vitamin D, this system was applied for vitamin D status classification as it has been devised by additionally considering the non-skeletal benefits of vitamin D.b. Serum Zinc: The 2-(5-bromo-2-pyridylazo)-5-(N-propyl-N-sulfopropylamino)-phenol (5-Br-PAPS) method was used for estimating serum zinc by colorimetry (Proton Biologicals India Pvt. Ltd.; Linearity limit - up to 500 µg/dL). The lower cut-offs for serum zinc are based on the guidelines suggested by IZiNCG Technical Brief \[[@B37]\]: \< 10 years, 65 µg/dL; male participants ≥ 10 years, 74 µg/dL; female participants ≥ 10 years, 70 µg/dL.

Infection data collection and scoring technique
-----------------------------------------------

To collect information on infection-related symptoms of the participant, a validated questionnaire was administered by trained social workers to the primary caregiver \[[@B38]\]. Information on common infections (URTI, gastrointestinal and others, i.e. eye, skin, urinary tract infections) were collected by recording details on the duration, frequency and severity of infection-related symptoms. Data were collected every fortnight during the trial period, and data from two fortnights were collated to obtain information related to infections suffered each month. Additional details related to the questionnaire components, its administration, and the scoring technique have been published elsewhere \[[@B39]\].

System illness scores (i.e. URTI Score or Gastrointestinal Score) were computed and are expressed as percentages, based on the maximum score that could be attained. Also, a total infection score was computed as a composite of URTI, gastrointestinal, skin and urinary tract infection scores.

Depending on the scores obtained, URTI and total infection score were classified as follows: \< 5, no or mild infection; 5 to 25, mild to moderate infection; and \> 25, severe infection \[[@B39]\].

Statistical analysis
--------------------

Past studies have reported a difference of 8--20% in the infection rates between the supplemented group and control group \[[@B40]\]. Thus, to detect a difference of 16% between supplemented and control group, we estimated a sample size of 156/group with 80% power and 5% level of significance.

The primary outcome measure was occurrence of infections (URTIs and total infections) in the three study arms at endline. Secondary exploratory outcomes include change in infection status according to endline serum 25(OH)D and zinc status and change in biochemical status from baseline. Statistical analysis was performed using the IBM SPSS Statistics for Windows (version 21.0.2012, Armonk, NY: IBM Corp) software. The one-sample Kolmogorov-Smirnov test was used to test the normality of variables before further analysis was carried out. The results are expressed as mean ± standard deviation (SD). ANOVA was applied to test differences between various parameters among the supplementation groups. The Kruskal-Wallis Test was used for non-normal variables. Paired Samples T-Test was used to compare the baseline to endline differences. For non-normal paired variables, the Wilcoxon Signed-Rank test was applied. Histograms were drawn to determine frequency of children within different URTI and total infection categories, at baseline and endline.

Intention-to-treat analysis was performed for all children who were randomized and completed the trial. Per-protocol analysis included all children who completed the trial without any protocol violations. Post-hoc analysis performed included association of infection status with endline vitamin D and zinc status, and change in biochemical status from baseline.

RESULTS
=======

CONSORT diagram for participant flow
------------------------------------

The trial CONSORT diagram is presented in [Fig. 1](#F1){ref-type="fig"}. Within a few days of allocation and start of supplementation, 7 participants left the school as their families moved out of town. During the intervention period, 12 more participants left the school, while 5 discontinued the intervention. 45 participants were lost to follow-up during endline data collection due to absenteeism from school, and as a result, their data were not obtained. For the per-protocol analysis, 2 participants were excluded due to poor compliance to supplementation (\< 50%), and 1 participant was excluded because her weight for age z-score was \< −4.0. Thus, complete data at baseline and endline were available for 363 participants (197 boys and 166 girls): 120 in the vitamin D arm, 119 in the zinc arm, and 124 in the placebo arm. Considering dropouts and loss to follow-up during the intervention period, the post-facto power of the trial was estimated at 0.73.

No significant differences were observed in gender, height and weight z-scores, socio-economic status, infection scores and nutrient intakes, when comparing participants who completed the trial and those who did not. However, the ages of participants included in the final analysis were significantly lower than those who did not complete the trial (8.0 ± 1.2 vs. 8.5 ± 1.3 years; *P* \< 0.001).

The mean compliance percentage was 88 ± 8% with no significant difference in compliance across the three trial arms; 50% participants had ≥ 90% compliance, 46% between 70 to 89%, and 4% were \< 70%.

The baseline characteristics of the participants are presented in [Table 1](#T1){ref-type="table"}.

Anthropometric characteristics
------------------------------

Age and anthropometric characteristics of the participants at baseline were similar for all three study arms ([Table 1](#T1){ref-type="table"}). Stunting (HAZ \< −2.0) was noted in 10% participants, 18% were found to be underweight (WAZ \< −2.0), and 15% exhibited thinness (i.e. BAZ \< −2.0).

Lifestyle
---------

Majority of the participants (90%) belonged to the middle socio-economic status, while 6% belonged to low socio-economic status and 4% to high socio-economic status \[[@B29]\]. No significant differences in socio-economic status were observed between genders, supplementation groups, or trial time points (i.e. baseline and endline).

The mean environment score was 63% and personal hygiene score was 87%, with no differences noted between gender, supplementation groups or trial time points \[[@B31][@B32]\].

Sunlight exposure was also similar between supplementation groups at the two trial timepoints, with most participants reporting 2 hours or more of sunlight exposure (81% at baseline and 85% at endline). A significantly (*P* \< 0.05) greater percentage of boys (36%) reported more than 2 hours of sunlight exposure compared to girls (25%).

Nutritional intakes
-------------------

Nutritional intakes of participants at both time-points were substantially lesser than the RDA for age and sex, with intakes of micronutrient less than 50% of the RDA.

There were no dietary sources of vitamin D in the foods consumed. Participants in the vitamin D group received 1,000 IU of cholecalciferol and 500 mg of calcium. Their calcium intake (inclusive of calcium supplement) was determined to be 743 ± 54 mg calcium/day during the period of supplementation (119% of the RDA for calcium). Compared to subjects in the placebo and zinc group who were consuming an average of 230 mg calcium per day (38% of RDA), the calcium intake of participants in the vitamin D group was 200% higher. Their dietary calcium to phosphorus ratio thereby increased to 1.4:1, whereas the placebo and zinc group participants had a dietary calcium to phosphorus ratio of 0.4:1.

For participants in the zinc group, the total intake of zinc (including zinc supplement) was 13 ± 0.6 mg/day during the supplementation period, enabling them to meet 160% of their RDA for zinc. The zinc intake was about 300% higher than participants in the placebo and vitamin D group, whose diets supplied 3 ± 1 mg zinc per day (36% of RDA).

Biochemical parameters
----------------------

Serum 25(OH)D: The baseline mean serum 25(OH)D concentration was determined to be 58.4 ± 10.3 nmol/L, with no significant difference between genders or among the three supplementation groups. In the group receiving vitamin D-calcium supplementation, the serum 25(OH)D concentrations significantly increased by 34% (from 59.7 ± 10.9 nmol/L to 80 ± 23.3 nmol/L) subsequent to 6 months of supplementation (*P* \< 0.0001). [Fig. 2](#F2){ref-type="fig"} illustrates the change in 25(OH)D status in the three groups, from baseline to endline.

Serum Zinc: The mean serum zinc concentration at baseline was 72.3 ± 28.2 µg/dL, and the concentrations were similar among the three groups. Following zinc supplementation for 6 months, no significant improvement was observed in serum zinc levels in the group receiving the zinc supplement. The mean serum zinc concentration of the zinc group at endline was 65.2 ± 20.4 µg/dL, with no differences noted among the three groups. Zinc deficiency was found in 45% of the participants.

Infection status
----------------

a\. Upper Respiratory Tract Infection (URTI): A positive trend in the distribution pattern of URTI was noted in each supplementation group (*P* \< 0.0001). In the vitamin D group, the percentage of participants having no or mild URTI (URTI score \< 5) increased from 38% at baseline to 65% at endline, and the percentage with high URTI scores decreased. Similarly, in the zinc arm, the percentage of participants with no or mild URTI increased from 39% at baseline to 56% at endline. In the placebo group, the percentage of participants with a URTI score of \< 5 increased from 33% to 59% after 6 months, and the percentage of participants with high URTI scores decreased compared to baseline.

b\. Total Infection: Results obtained when comparing total infection scores at baseline and endline among the three supplementation groups were similar to those of URTI. After the 6 months supplementation period, the percentage of participants with no or mild total infection (TI scores \< 5) were significantly increased in all three groups, with a corresponding decrease of percentage participants with high TI scores. The percentage of participants with no or mild total infections increased from 32% to 57% in the vitamin D group, 23% to 47% in the zinc group, and 23% to 53% in the placebo group (*P* \< 0.0001).

While the occurrence of infections reduced significantly in all three groups, we found no significant differences when comparing reduced occurrence of URTI or total infections in the supplemented groups versus the placebo.

Infection status according to vitamin D status
----------------------------------------------

Since no changes were detected in serum zinc status following zinc supplementation, results of URTI and total infection status (i.e. episodes, duration and score) relating to biochemical status are presented only for the vitamin D arm. At endline, the number of participants who were vitamin D deficient following supplementation was only 2%; hence, the participants who were deficient were pooled with those who were insufficient.

[Table 2](#T2){ref-type="table"} summarizes the endline infection status with respect to the endline serum 25(OH)D levels. Although no significant differences were found in URTI and total infection status between vitamin D insufficient and sufficient participants, a trend of lower URTI and total infection status was observed in the vitamin D sufficient participants.

Additionally, we evaluated URTI and total infection status in participants categorized according to their change in serum 25(OH)D concentrations, i.e., improvement versus relatively unchanged serum 25(OH)D levels, following vitamin D-calcium supplementation ([Table 3](#T3){ref-type="table"}). No significant differences were observed in the infection status at baseline or endline between the improved 25(OH)D group versus the unchanged 25(OH)D group.

We further determined that in the group with improved 25(OH)D levels, URTI and total infection status (viz., the number of episodes, duration of infection and infection score) was significantly reduced when compared to baseline (*P* \< 0.0001). However, no statistical significance was observed for the change in infection status in the 25(OH)D unchanged group ([Table 3](#T3){ref-type="table"}).

Intention to treat analysis
---------------------------

The intention to treat analysis were similar to results obtained in the per-protocol analysis. When compared as a whole with the placebo group, improvement in vitamin D group infection status was at par with the placebo group. Similar results were obtained when considering the vitamin D status; improved vitamin D concentrations in the vitamin D group demonstrated improved infection status.

DISCUSSION
==========

Our trial population of 6--12-year-old children from a rural setting comprised a majority who received more than 2 hours of sunlight exposure, had a mean serum 25(OH)D concentration of 58.4 ± 10.3 nmol/L, and 45% revealed zinc deficiency. No significant reduction was observed in the occurrence of infections, in either the vitamin D group or the zinc group when compared to the placebo group. However, we observed a trend of lower URTI and total infections in participants who were vitamin D sufficient as compared to vitamin D insufficient participants. We further observed significant improvement in the URTI and total infection status in participants with improved serum 25(OH)D concentrations as compared to participants with unchanged levels. Majority of the trial participants belonged to the middle socio-economic strata, with similar living conditions and personal hygiene habits.

To our knowledge, this is the first intervention trial in a rural population of 6--12-year-old children, undertaken to determine the effect of supplementation with either vitamin D or zinc, on the occurrence of common infections.

The anthropometric characteristics of all participants across the three trial arms at baseline were similar. Prevalence of stunting (10%) and underweight (18%) were comparable to those reported in rural schoolchildren aged 5--14 years from Bengaluru (17% stunting and 17% underweight) \[[@B41]\].

In all three groups, we observed a significant increase in the percentage of children with no to mild URTI as well as no to mild total infections, as compared to the baseline, with consequent reduction in the percentage of children with severe infections. Overall, no improvements were observed when comparing the supplementation groups with placebo group.

Our study revealed significant improvement in the vitamin D status of participants, following daily supplementation for 6 months with 1,000 IU vitamin D and 500 mg calcium. The percentage of participants in the vitamin D group with sufficient 25(OH)D concentrations rose from 9% at baseline to 50% at endline ([Fig. 2](#F2){ref-type="fig"}). The efficacy of this dose of vitamin D supplementation has been documented by us in an earlier publication \[[@B42]\].

Next, we assessed the infection status at endline by considering the different categories of endline serum 25(OH)D status of participants in the vitamin D arm. No statistical differences were observed between participants when comparing the 25(OH)D status. However, a trend of lower infection status was observed among participants who were vitamin D sufficient. Additionally, assessment for alterations in the infection status within categories of changed vitamin D concentrations revealed that improved vitamin D concentrations resulted in significant improvement in the infection status.

Vitamin D supplementation to reduce infections in children has yielded varied results. Martineau et al. \[[@B43]\], in their meta-analysis to test the effect of vitamin D on the incidence of acute respiratory tract infections, reported that while vitamin D exerted a protective effect against respiratory infections, the benefits were largely experienced by participants who were severely vitamin D deficient. They report that participants with baseline serum 25(OH)D concentration \< 25 nmol/L who received frequent low doses of vitamin D supplements showed the maximum beneficial effect against respiratory tract infections.

In the current trial, while we administered frequent, low dose vitamin D supplements which produced a statistically significant improvement in the vitamin D status, none of the trial participants were severely vitamin D deficient. At baseline, only 20% participants in the vitamin D arm were deficient (serum 25OHD \< 50 nmol/L), with minimum serum 25(OH)D concentration being 40 nmol/L. Based on previous finding of prevalence of up to 75% deficiency among children in rural South India in spite of them having around 8 hours of sunlight exposure \[[@B7]\], we had expected a majority in this population to be vitamin D deficient. However, most of the participants (70%) in the current trial had insufficient vitamin D, and only about 20% were deficient. We therefore speculate that since the participants in our study were not severely vitamin D deficient, the reduction in occurrence of URTI or total infections in participants in the vitamin D group as compared to placebo group was not significant. However, we observed a trend of lower infection status in vitamin D sufficient participants and significantly improved infection status in participants with improved 25(OH)D levels.

In the zinc arm of the trial, we found that zinc supplementation exerted no benefit in improving the zinc status of the participants. No significant differences in serum zinc concentrations were observed among participants who received zinc supplement and those who did not. The following factors may be responsible for inability of the supplement to improve zinc status. 1) Insufficient or inadequate amount of supplemental zinc administered: While reports suggest that supplementation with up to 10 mg of zinc may be considered for preventive supplementation in children under 14 years of age, there are as yet no guidelines available for preventive zinc supplementation \[[@B44]\]. Hence, we administered a supplement that would meet at least 1 RDA of zinc (7 to 9 mg/day) for the trial participants. Other researchers have used higher zinc doses for younger children (10 mg to 70 mg zinc daily for children aged 22 to 66 months) \[[@B45]\]. 2) Reduced bioavailability of zinc from the supplement due to other components in the supplement which may have interfered with zinc absorption \[[@B25]\]. While conflicting results of the effect of zinc supplementation on incidence of childhood infections like common colds, diarrhea, etc. have been reported, authors have recognized the benefits of zinc supplementation for zinc deficient populations \[[@B25][@B44]\]. Thus, further investigations into the effect of zinc supplementation on immune response in children are warranted.

This trial has some limitations. One limitation was that the recording of infection-related data was performed using a questionnaire, and we did not have any additional objective assessment of infections suffered by the participant. However, infection data was recorded regularly (every fortnight) to avoid recall bias. Additionally, we recorded the numbers of days and reason for absence from school, details of treatment taken, home remedies administered, and details of medical reports, if any. This helped in validating the data collected by the questionnaire, thereby resulting in accurate recording of infections suffered by the participants. Considering that the effect of vitamin D supplementation on the immune response is more likely observed in participants who are severely vitamin D deficient (i.e., serum vitamin D \< 25 nmol/L), an important limitation of this trial was that none of the participants were severely deficient. This may be one of the reasons that we were unable to detect a decrease in occurrence or duration of infections greater than that observed in the placebo group.

Thus, in 6--12-year-old children having poor nutritional intake, adequate sunlight exposure, and insufficient vitamin D status, supplementation with 1,000 IU vitamin D and 500 mg calcium helps in improving the vitamin D status but had no effect on the occurrence of childhood infections. Improvement in vitamin D concentrations and attainment of vitamin D sufficiency could exert beneficial effects on the infection status and needs to be investigated further. For success of zinc supplementation among these children, higher dosages of zinc supplement need to be administered in future studies.
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###### Baseline characteristics of the participants according to study arms
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                              Vitamin D-Calcium    Zinc             Placebo
  --------------------------- -------------------- ---------------- -----------------
  N                           120                  119              124
  Gender (%)                                                        
   Boys                       55                   56               52
   Girls                      45                   44               48
  Age (yrs)                   8.2 ± 1.2            7.9 ± 1.2        7.9 ± 1.1
  Height (cms)                120.7 ± 7.4          120.0 ± 8.1      119.1 ± 6.9
  HAZ                         -1.0 ± 0.8           -0.8 ± 0.9       -0.9 ± 0.8
  Weight (kg)                 19.8 ± 3.5           19.9 ± 4.8       19.2 ± 3.1
  WAZ                         -1.3 ± 0.7           -1.2 ± 1.0       -1.3 ± 0.8
  BMI (kg/m^2^)               13.5 ± 1.3           13.6 ± 1.8       13.5 ± 1.3
  BAZ                         -1.2 ± 0.7           -1.1 ± 1.0       -1.2 ± 0.8
  Socio-economic status (%)                                         
   Low                        5                    7                5
   Middle                     92                   88               89
   High                       3                    5                6
  Environment (%)                                                   
   Very Good                  5^\*\*^              11               11
   Good                       46^\*\*^             60               55
   Fair                       29^\*\*^             16               24
   Poor                       20^\*^               13               10
  Personal hygiene (%)                                              
   Very Good                  30                   30               25
   Good                       51                   47               52
   Fair                       14                   17               18
   Poor                       5                    6                5
  Sunlight exposure (%)                                             
   \<2 hours                  15                   20               20
   2 to 2.5 hours             49                   50               52
   \> 2.5 hours               36                   30               28
  Biochemical parameters                                            
   Serum 25(OH)D (nmol/L)     60.2 ± 11.9          58.1 ± 9.9       57.7 ± 10.0
   Serum Zinc (μg/dL)         67.3 ± 29.0          74.7 ± 28.3      77.0 ± 30.8
  Nutritional intakes                                               
   Calories (kcal)            949 ± 182 (58)^\*^   989 ± 203 (62)   1028 ± 194 (64)
   Protein (g)                20 ± 4 (75)^\*^      22 ± 5 (81)      22 ± 5 (83)
   Calcium (mg)               189 ± 52 (31)^\*^    207 ± 60 (34)    218 ± 65 (36)
   Zinc (mg)                  3 ± 1 (35)           3 ± 1 (36)       3 ± 1 (37)

Values are expressed as means ± SD or percentage (%).

HAZ, Height for age Z-score; WAZ, Weight for age Z-score; BAZ, BMI for age Z-score

^\*^Significantly different from Placebo (*P* \< 0.05)

^\*\*^Significantly different from Zinc (*P* \< 0.05)

###### Endline infection status among categories of endline serum 25(OH)D

![](nrp-14-117-i002)

  Parameters                           Vitamin D sufficiency (≥ 75 nmol/L) (53)^†^   Vitamin D insufficiency (\< 75 nmol/L) (54)^†^
  ------------------------------------ --------------------------------------------- ------------------------------------------------
  Serum 25(OH)D (nmol/L)               96.9 ± 21.8                                   63.4 ± 7.6^\*^
  Upper respiratory tract infections                                                 
   Episodes                            0 ± 1                                         0 ± 1
   Duration (days)                     2 ± 3                                         2 ± 4
   URTI score                          7 ± 11                                        9 ± 13
  Total infections                                                                   
   Episodes                            0 ± 1                                         1 ± 1
   Duration (days)                     2 ± 4                                         3 ± 4
   Total infection score               11 ± 15                                       13 ± 16

Values are expressed as means ± SD.

^†^Figures in parentheses are number of participants.

^\*^Significantly different from Vitamin D Sufficiency (*P* \< 0.0001).

###### Infection status among categories of change in serum 25(OH)D concentrations in the vitamin D arm

![](nrp-14-117-i003)

  Parameters^†^                        Improved serum 25(OH)D (89)^‡^   Unchanged serum 25(OH)D (18)^‡^                     
  ------------------------------------ -------------------------------- --------------------------------- ----------------- ------------------
  Serum 25(OH)D (nmol/L)               58.0 ± 10.4                      84.1 ± 23.2^\*^                   66.9 ± 11.6^\*^   59.6 ± 8.7^\*\*^
  Upper respiratory tract infections                                                                                        
   Episodes                            1 ± 1                            0 ± 1^\*^                         1 ±1              1 ± 1
   Duration (days)                     4 ± 4                            2 ± 3^\*^                         4 ±5              3 ± 5
   URTI score                          14.5 ± 13.8                      7.9 ± 11.7^\*^                    13.7 ± 13.5       10.4 ± 13.4
  Total infections                                                                                                          
   Episodes                            1 ± 1                            0 ± 1^\*^                         1 ±1              1 ± 1
   Duration (days)                     5 ± 5                            3 ± 4^\*^                         5 ±6              4 ± 5
   Total infection score               19.2 ± 16.3                      11.4 ± 14.8^\*^                   19.3 ± 17.0       15.9 ± 18.3

Values are expressed as means ± SD.

^†^All parameters were non-normal and non-parametric tests have been used to test differences between groups.

^‡^Figures in parentheses are number of participants.

^\*^Significantly different from baseline of improved serum 25(OH)D (*P* \< 0.0001).

^\*\*^Significantly different from endline of improved serum 25(OH)D (*P* \< 0.0001) and from baseline of unchanged serum 25(OH)D (*P* \< 0.0001).
